8-K
filed May 15, 2025, 7:59 PM ET
ticker BCLI
CIK 0001137883
earnings
confidence high
sentiment neutral
materiality 0.65
BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment
BRAINSTORM CELL THERAPEUTICS INC.
2025-Q1 EPS
reported -$0.45
vs consensus -$0.99
▲ beat
(+54.5%)
- Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
- Cash, equivalents restricted cash $1.8M at March 31, 2025; R&D $1.3M, G&A $1.8M.
- Submitted IND amendment for Phase 3b NurOwn trial (ENDURANCE) targeting ~200 early ALS patients with SPA.
- Trial listed on ClinicalTrials.gov (NCT06973629) with 15 clinical sites; data at ISCT and ALS Summit.
- Conference call rescheduled to May 19, 2025 at 8:30 AM ET.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-25-049581
- form_type
- 8-K
- ticker
- BCLI
- cik
- 0001137883
- company_name
- BRAINSTORM CELL THERAPEUTICS INC.
- filed_at
- 2025-05-15T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:47.631645+00:00
- generated_at
- 2026-05-21T04:32:55.085972+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-25-049581
- json_url
- https://secwatch.observer/filing/0001104659-25-049581.json
- markdown_url
- https://secwatch.observer/filing/0001104659-25-049581.md
- text_url
- https://secwatch.observer/filing/0001104659-25-049581.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/0001104659-25-049581-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RMCF
Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38
Rocky Mountain Chocolate Factory, Inc.
June 1, 2026, 9:15 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PKE
Park Aerospace Q4 sales up 43% to $24.2M; EPS $0.19 vs $0.06 YoY; full-year net earnings double to $11.3M
PARK AEROSPACE CORP
May 28, 2026, 4:29 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
PLUS
ePlus Q4 net sales +20.6% to $576M, diluted EPS $0.78; FY2026 net sales +22.1% to $2.44B; dividend raised to $0.27
EPLUS INC
May 28, 2026, 4:25 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.